Relative Bioavailability of Two Newly Developed FDC Tablet Strengths (25mg/1000mg and 12.5mg/750mg) of Empagliflozin/Metformin Extended Release Compared With the Free Combination of Empagliflozin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study)
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Empagliflozin/metformin (Primary) ; Empagliflozin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 27 Jan 2014 Status changed from active, no longer recruiting to completed as reported by the ClinicalTrials.gov record.
- 10 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Nov 2013 New trial record